Sienna Biopharmaceuticals Establishes Corporate Advisory

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
92
Sienna Biopharmaceuticals Establishes Corporate Advisory Board

WESTLAKE VILLAGE, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced the formation of a Corporate Advisory Board that will provide scientific, clinical and strategic advice to the Company’s senior management. The Corporate Advisory Board comprises accomplished and highly regarded medical opinion leaders within dermatology and aesthetics who have specific scientific knowledge and clinical experience in psoriasis, atopic dermatitis (eczema), pruritus (itch), acne and laser medicine.

“As a company focused on the needs of dermatologists and their patients, we are excited to announce this important step in Sienna’s corporate development,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “The perspective and insight that each distinguished member of this Advisory Board can bring is invaluable. The breadth of their collective knowledge and experience spans all of our current development programs. We look forward to collaborating with them as we develop and commercialize our innovative multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients.”

“With plans for five programs to be in the clinic within the first half of 2018, multiple data readouts expected in the second half of 2018 and a vast untapped potential with our innovative Topical by Design™ and Topical Photoparticle Therapy™ platforms, this is exactly the right time for us to engage with these leading scientists and practitioners,” said Paul F. Lizzul, M.D., Ph.D., Chief Medical Officer of Sienna. “They have unique and varied viewpoints from years of research and clinical practice. They share our passion for helping dermatology and aesthetics patients improve their lives. We are eager for their input as we work diligently to bring to market a pipeline of safe, effective and differentiated products for patients with significant unmet medical needs.”

The members of Sienna’s inaugural Corporate Advisory Board include:

  • Mathew Avram, M.D., J.D., director of the Mass General Dermatology Laser & Cosmetic Center, director of laser, cosmetics and dermatologic surgery at Massachusetts General Hospital and associate professor of dermatology at Harvard Medical School
  • Diane Berson, M.D., in private practice in New York, associate professor of dermatology at Cornell University’s Weill Cornell Medical College and assistant attending dermatologist at New York-Presbyterian Hospital
  • Robert Bissonnette, M.D., M.Sc., founder and president of Innovaderm Research Inc. in Montreal and former associate professor of dermatology at the University of Montreal
  • Jeffrey S. Dover, M.D., co-director of SkinCare Physicians in Chestnut Hill, Mass., associate professor of clinical dermatology at Yale University School of Medicine and associate professor of dermatology at the Brown University Warren Alpert Medical School
  • Mitchel Goldman, M.D., medical director of Cosmetic Laser Dermatology and West Dermatology, California and volunteer clinical professor of dermatology at the University of California, San Diego
  • Emma Guttman, M.D., Ph.D., Sol and Clara Kest professor of dermatology, vice chair for research at the department of dermatology, director of the Center for Excellence in Eczema and director of the laboratory of inflammatory skin diseases at the Icahn School of Medicine at Mount Sinai
  • Ethan Lerner, M.D., Ph.D., associate professor of dermatology at Harvard Medical School, assistant dermatologist at Massachusetts General Hospital and founder and chairman of Lerner Medical Devices
  • Alan Menter, M.D., chairman of the division of dermatology at Baylor University Medical Center, chair of research for dermatology at Baylor Research Institute, principal faculty at Texas A&M University Health Science Center and clinical professor of dermatology at the University of Texas Southwestern Medical School
  • Sonja Ständer, Dr. med., professor of dermatology and clinical neurodermatology at the Center for Chronic Pruritus, department of dermatology, Münster University Hospital in Germany
  • Gil Yosipovitch, M.D., professor of dermatology and director of the Miami Itch Center at the University of Miami Miller School of Medicine

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.

For more information, visit the Company’s website at www.SiennaBio.com .

Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements related to the potential to commercialize a multi-asset pipeline of topical therapies, Sienna’s plans and expectations with regard to its clinical development programs, data readouts and timing thereof, and the potential of the Topical by Design and Topical Photoparticle Therapy platforms. Such forward-looking statements involve substantial risks and uncertainties that could cause Sienna’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug  development process, including the clinical trial enrollment process, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Sienna’s ability to successfully protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations and the availability or commercial potential of Sienna’s product candidates. Sienna undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Sienna’s most recent Quarterly Report on Form 10-Q and any subsequent current and periodic reports filed with the Securities and Exchange Commission.

Contact (Investors and Media):

Ric Peterson Chief Financial Officer rpeterson@siennabio.com 818-629-2232

Sean Andrews Senior Director, Investor Relations sandrews@siennabio.com 818-629-2244 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Happiest Minds Extends Absa Banking Platform Reach

Updated Category News Views 34

Mauritius just handed Happiest Minds a useful, if modest, banking-tech scorecard. On November 19, 2026, the company said its cloud-native Arttha platform had been deployed to support selected capabilities within Spark by Absa, a digital banking and lifestyle app from Absa Bank (Mauritius). This is not the sort of announcement that lets anybody pencil in a giant revenue...

Continue Reading
California Budget Warning Puts Reserves Back in Focus

Updated Category News Views 118

California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 0

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 34

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 74

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
JOYY Q3 Growth Shows More Than Livestreaming Muscle

Updated Category News Views 39

Revenue finally has more than one pair of legs at JOYY, and that matters a whole lot more than a flashy quarterly headline. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% from the prior quarter. Those are not microscopic moves, and the composition is the part that deserves the hard stare. JOYY is still rooted in...

Continue Reading
A Hybrid Book Bets on Muscles, Myth, and Machines

Updated Category News Views 66

Few publishing pitches ask readers to carry a barbell into Tartarus, but A R Quigley is plainly not chasing the middle of the bookstore. Doctrina Machina Learning Machine, released by Palmetto Publishing in November 2026, welds together a strength-training guide and an underground military science-fiction war story. That is an odd little contraption, no use pretending...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 188

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 169

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading

Top 5 Most Recently Viewed Articles

Melissa Tapanes Llahues Takes Charge as BASF President

Updated Category News Views 200

Melissa Tapanes Llahues Installed as President of BASF Bercow Radell Fernandez Larkin & Tapanes Partner continues her leadership across the development sectors Melissa Tapanes Llahues, an esteemed land use attorney and civic leader, has been officially installed as President of the Builders Association of South Florida (BASF), a key player in the region's development...

Continue Reading
Petco's Q2 2025 Results: A Look at Performance and Projections

Updated Category News Views 217

Petco's Q2 2025 Financial Results Overview Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) has revealed its financial performance for the second quarter of 2025, showcasing various achievement metrics and prospects for the remainder of the fiscal year. With a commitment to ongoing improvement, Petco has raised its earnings outlook and emphasized a strong economic...

Continue Reading
Empowering Women in STEM: A Transformative Networking Opportunity

Updated Category News Views 309

Empowering Women in STEM: A Transformative Networking Opportunity On November 12, a groundbreaking event titled "Connecting Our Talents; Women in STEM" will take place, bringing together female STEM students from various educational institutions. This event aims to highlight emerging talents and connect them with industry professionals, creating an invaluable network for...

Continue Reading
Analyzing Market Sentiment for Simpson Manufacturing Co Inc.

Updated Category News Views 260

Understanding Market Sentiment for Simpson Manufacturing Co Inc Simpson Manufacturing Co Inc's (NYSE: SSD) short interest has experienced a notable increase, with reports indicating a surge of 6.31% since the latest update. Currently, approximately 1.10 million shares have been sold short, which accounts for about 3.37% of the total shares available for trading. This...

Continue Reading
Growth of Hemp-Based Foods Market: Insights and Trends

Updated Category News Views 104

The Hemp-Based Foods Market: A Growing Trend The hemp-based foods market is experiencing remarkable growth, with projections indicating it will hit $10.6 billion by 2033. This marks a significant increase from $5.4 billion in 2023, boasting a compound annual growth rate (CAGR) of 7.2%. This upward trend shows a clear shift in consumer preferences toward plant-based diets,...

Continue Reading